Biopharmaceutical company Daré Bioscience announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene. These interim findings support Ovaprene’s potential as a meaningful hormone-free alternative; there currently are no FDA-approved, hormone-free, monthly intravaginal contraceptives: https://finance.yahoo.com/news/positive-interim-phase-3-results-120000855.html